Technical Analysis for VERV - Verve Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.19 | 0.97% | 0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 0.97% | |
| Lower Bollinger Band Walk | Weakness | 0.97% | |
| Wide Bands | Range Expansion | 0.97% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 1% | 2 days ago |
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
| Up 2% | 2 days ago |
Get a Trading Assistant
- Earnings date: 05/07/2024
Verve Therapeutics, Inc. Description
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.4199 |
| 52 Week Low | 4.9 |
| Average Volume | 1,440,522 |
| 200-Day Moving Average | 11.53 |
| 50-Day Moving Average | 7.50 |
| 20-Day Moving Average | 5.84 |
| 10-Day Moving Average | 5.43 |
| Average True Range | 0.46 |
| RSI (14) | 28.06 |
| ADX | 26.14 |
| +DI | 15.64 |
| -DI | 27.29 |
| Chandelier Exit (Long, 3 ATRs) | 5.61 |
| Chandelier Exit (Short, 3 ATRs) | 6.29 |
| Upper Bollinger Bands | 6.78 |
| Lower Bollinger Band | 4.90 |
| Percent B (%b) | 0.16 |
| BandWidth | 32.31 |
| MACD Line | -0.65 |
| MACD Signal Line | -0.70 |
| MACD Histogram | 0.0528 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.46 | ||||
| Resistance 3 (R3) | 5.45 | 5.36 | 5.42 | ||
| Resistance 2 (R2) | 5.36 | 5.29 | 5.36 | 5.40 | |
| Resistance 1 (R1) | 5.27 | 5.25 | 5.32 | 5.28 | 5.38 |
| Pivot Point | 5.18 | 5.18 | 5.20 | 5.18 | 5.18 |
| Support 1 (S1) | 5.09 | 5.11 | 5.14 | 5.10 | 5.00 |
| Support 2 (S2) | 5.00 | 5.07 | 5.00 | 4.98 | |
| Support 3 (S3) | 4.91 | 5.00 | 4.97 | ||
| Support 4 (S4) | 4.92 |
